TD Cowen analyst Phil Nadeau has maintained their bullish stance on AURA stock, giving a Buy rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Phil Nadeau has given his Buy rating due to a combination of factors surrounding Aura Biosciences Inc’s current and future prospects. The company’s financial position appears stable with a cash reserve of approximately $161.9 million, which is expected to support operations into the first half of 2027. This financial runway provides a solid foundation for Aura to continue its research and development activities without immediate financial constraints.
Moreover, the progress in Aura’s clinical trials is a significant factor in the Buy rating. The pivotal Phase III trial for bel-sar in choroidal melanoma is advancing, with a substantial number of eligible patients identified and a steady enrollment pace. Additionally, the initial results from bel-sar’s trial in bladder cancer show promise, with ongoing trials expected to yield further data by mid-2026. These developments indicate a positive trajectory for Aura’s pipeline, supporting the optimistic outlook reflected in the Buy rating.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $22.00 price target.